Product image of Metformina + Pioglitazona Farmoz (Metformin Hydrochloride, Pioglitazone) supplied by GNH India

Metformina + Pioglitazona Farmoz

Active Ingredient:
Metformin Hydrochloride, Pioglitazone
Origin:
EU

Metformina + Pioglitazona Farmoz (Metformin Hydrochloride, Pioglitazone)

Metformin Hydrochloride and Pioglitazone, the active ingredients in Metformina + Pioglitazona Farmoz, are a biguanide and a thiazolidinedione presented as oral tablets for oral use. They are prescribed to improve glycemic control in adults with type 2 diabetes mellitus.
GNH India supplies Metformina + Pioglitazona Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Farmoz - Sociedade Técnico Medicinal, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metformina + Pioglitazona Farmoz is indicated for the management of type 2 diabetes mellitus, acting on glucose metabolism pathways.

  • Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
  • Combination therapy with other antidiabetic agents: provides additive insulin‑sensitising effect.
  • Adjunct to diet and exercise: helps achieve target HbA1c when lifestyle measures alone are insufficient.

How It Works

  • Metformin decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity by activating AMP‑activated protein kinase. Pioglitazone binds to peroxisome proliferator‑activated receptor‑γ (PPARγ), modulating gene expression to increase insulin sensitivity in adipose tissue, skeletal muscle and liver, thereby improving glucose uptake and utilization.

Side Effects

Common Side Effects

  • Nausea: mild to moderate gastrointestinal discomfort.
  • Diarrhea: increased stool frequency, usually transient.
  • Abdominal discomfort: bloating or cramping.
  • Weight gain: modest increase due to fluid retention.
  • Edema: peripheral swelling, especially in lower limbs.
  • Headache: occasional mild headache.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic disturbance.
  • Congestive heart failure: exacerbation due to fluid retention.
  • Hepatotoxicity: elevated liver enzymes or hepatitis.
  • Bone fracture: increased risk with long‑term use.
  • Bladder cancer: rare association reported with pioglitazone.

Precautions & Warnings

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters.

  • Renal function: evaluate eGFR and avoid use in severe renal impairment.
  • Hepatic function: check liver enzymes; discontinue if significant elevation occurs.
  • Cardiovascular status: monitor for signs of heart failure or edema.
  • Pregnancy and lactation: use only if potential benefit outweighs risk; data are limited.
  • Lactic acidosis risk: educate patients on recognizing symptoms and discontinue during acute illness.
  • Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Metformina + Pioglitazona Farmoz may interact with several concomitant medicines.

Major Interactions (Avoid)

  • Known hypersensitivity to metformin or pioglitazone: contraindicated.
  • Strong CYP2C8 inhibitors (e.g., gemfibrozil): may increase pioglitazone exposure.
  • Iodinated contrast agents: risk of acute renal failure, temporarily discontinue metformin.

Moderate Interactions (Monitor Closely)

  • Sulfonylureas or insulin: increased risk of hypoglycemia.
  • Loop diuretics: may exacerbate fluid retention and edema.
  • ACE inhibitors or ARBs: monitor renal function and potassium levels.

Frequently Asked Questions

Metformina + Pioglitazona Farmoz is a prescription oral medication used to improve blood glucose control in adults with type 2 diabetes mellitus. It combines two insulin‑sensitising agents, metformin and pioglitazone, to lower fasting and post‑prandial glucose levels when diet, exercise, or other therapies are insufficient.

Metformin Hydrochloride reduces hepatic glucose production and enhances peripheral insulin sensitivity by activating AMP‑activated protein kinase (AMPK). This leads to decreased gluconeogenesis, increased glucose uptake by muscles, and overall lower blood glucose concentrations.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for use during pregnancy and lactation are limited. The product should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformina + Pioglitazona Farmoz offers dual insulin‑sensitising mechanisms, unlike sulfonylureas which stimulate insulin release or SGLT2 inhibitors that increase urinary glucose excretion. This fixed‑dose combination can simplify regimens and provide additive glucose‑lowering effects, but individual patient factors determine the most appropriate therapy.

Store the tablets at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include lactic acidosis (particularly in patients with renal impairment), congestive heart failure due to fluid retention, hepatotoxicity, and, rarely, an increased risk of bladder cancer. Patients should be monitored for symptoms such as unexplained fatigue, shortness of breath, abdominal pain, or hematuria.

The product is contraindicated in patients with known hypersensitivity to metformin or pioglitazone, severe renal impairment (eGFR <30 mL/min/1.73 m²), active liver disease, or a history of lactic acidosis. It should also be avoided in individuals with uncontrolled heart failure.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Pioglitazone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT